Dingell, Stupak mull FDA inspection law

U.S. Reps. John Dingell, D-Mich., and Bart Stupak, D-Mich., are pondering tougher laws after the FDA failed to follow its own guidelines on the inspection of foreign drug plants. Stupak said he will look into legislation that makes it illegal to distribute a drug in the U.S. from a facility that has not undergone FDA inspection, in light of the agency's failure to inspect a Chinese plant that makes the active ingredient in Baxter's blood thinner heparin.

View Full Article in:

Boston Globe (tiered subscription model), The · Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT